AI Stock Analysis - Adaptimmune Therapeutics (ADAP)
Analysis generated October 22, 2025.
Adaptimmune Therapeutics is a biopharmaceutical company focused on developing novel cancer immunotherapy treatments. The company uses its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell technology to target and combat specific cancer cells effectively. Adaptimmune's pipeline includes multiple clinical-stage programs aimed at various cancers, providing innovative therapeutic options for patients with limited treatments.
Stock Alerts - Adaptimmune Therapeutics (ADAP)
 |
Adaptimmune Therapeutics | October 27 Price is up by 6.2% in the last 24h. |
|
Adaptimmune Therapeutics | October 24 Price is down by -10.7% in the last 24h. |
|
Adaptimmune Therapeutics | October 23 Price is down by -7.5% in the last 24h. |
|
Adaptimmune Therapeutics | October 22 Price is up by 9.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Adaptimmune Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 23,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,071 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 10,560 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.
| Price | $0.05 |
| Target Price | Sign up |
| Volume | 50,780,000 |
| Market Cap | $15M |
| Year Range | $0.04 - $0.35 |
| Dividend Yield | 0% |
| Analyst Rating | 63% buy |
| Industry | Biotechnology |
In the news
 |
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Given Average Recommendation of “Reduce” by AnalystsOctober 6 - ETF Daily News |
|
Adaptimmune Therapeutics Target of Unusually Large Options Trading (NASDAQ:ADAP)September 20 - ETF Daily News |
|
Short Interest in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Rises By 127.2%September 13 - ETF Daily News |
|
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives Consensus Rating of “Hold” from BrokeragesSeptember 11 - ETF Daily News |
|
Short Interest in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Rises By 32.6%September 10 - ETF Daily News |
|
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives $1.35 Consensus PT from BrokeragesAugust 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 14M | 2.5M | 11M | -30M | -26M | -0.120 |
| Q1 '25 | 7.3M | 880,000 | 6.4M | -48M | -43M | -0.180 |
| Q4 '24 | 3.2M | 2.9M | 3.2M | -74M | -68M | -0.050 |
| Q3 '24 | 41M | 2.8M | 41M | -18M | -13M | -0.010 |
| Q2 '24 | 128M | 2.6M | 126M | 70M | 71M | 0.240 |
Insider Transactions View All
| Bertrand William C JR filed to sell 986,352 shares at $0. August 29 '25 |
| Behbahani Ali filed to sell 14,671,794 shares at $0. August 19 '25 |
| EcoR1 Capital, LLC filed to sell 100,371,882 shares at $0.1. July 30 '25 |
Similar companies
Read more about Adaptimmune Therapeutics (ADAP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, x mentions, news mentions & customer reviews.
What is the Market Cap of Adaptimmune Therapeutics?
The Market Cap of Adaptimmune Therapeutics is $15M.
What is the current stock price of Adaptimmune Therapeutics?
Currently, the price of one share of Adaptimmune Therapeutics stock is $0.05.
How can I analyze the ADAP stock price chart for investment decisions?
The ADAP stock price chart above provides a comprehensive visual representation of Adaptimmune Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adaptimmune Therapeutics shares. Our platform offers an up-to-date ADAP stock price chart, along with technical data analysis and alternative data insights.
Does ADAP offer dividends to its shareholders?
As of our latest update, Adaptimmune Therapeutics (ADAP) does not offer dividends to its shareholders. Investors interested in Adaptimmune Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Adaptimmune Therapeutics?
Some of the similar stocks of Adaptimmune Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
